A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.Serena Di Cosimo, José Baselga, J. C. Bendell et al.|Journal of Clinical Oncology|2010Cited by 67
Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Clinical Cancer Research|2014Cited by 56
Supplementary Methods, Tables 1 - 4, Figure Legends from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Unknown|2023Cited by 0
Supplementary Figure 3 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Unknown|2023Cited by 0
Supplementary Figure 4 from Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical TrialSerena Di Cosimo, José Baselga, Sriram Sathyanarayanan et al.|Unknown|2023Cited by 0